Nasdaq warns Traws Pharma (Nasdaq: TRAW) over sub-$1.00 bid price
Rhea-AI Filing Summary
Traws Pharma, Inc. reported that on July 29, 2026 it received a notification letter from the Nasdaq Listing Qualifications Department stating that its common stock is not in compliance with the Nasdaq Capital Market minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price has been below $1.00 per share for at least 30 consecutive business days. The notice does not immediately affect the company’s Nasdaq listing.
Traws Pharma has 180 calendar days, until January 25, 2027, to regain compliance, which requires a closing bid price at or above $1.00 per share for at least 10 consecutive business days, a period Nasdaq may extend to up to 20 days. If compliance is not regained, Nasdaq may grant a second 180‑day grace period if other listing standards are met and the company plans to cure the deficiency. Otherwise, the stock may be subject to delisting, which the company could appeal. Traws Pharma states it will monitor its bid price and consider options, but there is no assurance of regaining compliance.
Positive
- None.
Negative
- Nasdaq minimum bid price deficiency increases the risk of Traws Pharma’s common stock being delisted if it cannot restore a bid of at least $1.00 within the allowed compliance periods.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Key Figures
Minimum bid price requirement: $1.00 per share
Non-compliance trigger period: 30 consecutive business days
Initial compliance period: 180 calendar days
+2 more
5 metrics
Minimum bid price requirement
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) threshold for continued listing
Non-compliance trigger period
30 consecutive business days
Closing bid below $1.00 for at least this period
Initial compliance period
180 calendar days
From July 29, 2026 to January 25, 2027 to regain compliance
Price cure window
10 consecutive business days
Bid must close at or above $1.00 for at least this period
Potential second grace period
180 calendar days
May be granted if other listing standards are met
Key Terms
Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), Nasdaq Capital Market, Nasdaq Listing Qualifications Department, +1 more
5 terms
Minimum Bid Price Requirement regulatory
"not in compliance with the minimum bid price requirement for continued listing"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”)"
Nasdaq Capital Market regulatory
"continued listing on The Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Nasdaq Listing Qualifications Department regulatory
"received a notification letter from the Nasdaq Listing Qualifications Department"
The Nasdaq Listing Qualifications Department is the team at the Nasdaq stock market that monitors whether listed companies meet the exchange’s rules for things like minimum share price, market value, timely financial reporting and governance. Its role matters to investors because its notices, warnings or enforcement actions—ranging from reminders to suspension or delisting—can sharply affect a stock’s trading, liquidity and perceived risk; think of it as the referee enforcing the marketplace’s entry and conduct rules.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What Nasdaq notice did Traws Pharma (TRAW) receive on July 29, 2026?
Nasdaq notified Traws Pharma that its common stock no longer meets the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), after trading below $1.00 for at least 30 consecutive business days, triggering a formal deficiency period.
How long does Traws Pharma (TRAW) have to regain Nasdaq bid-price compliance?
Traws Pharma has 180 calendar days, until January 25, 2027, to regain compliance. It must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, subject to Nasdaq’s discretion to extend that period.
What happens if Traws Pharma (TRAW) restores its bid to $1.00 on Nasdaq?
If Traws Pharma’s closing bid is at or above $1.00 for at least 10 consecutive business days before January 25, 2027, Nasdaq will issue written confirmation that the company has regained compliance with the minimum bid price requirement and the matter will be resolved.
Can Traws Pharma (TRAW) receive a second grace period from Nasdaq?
If Traws Pharma fails to regain compliance by January 25, 2027, Nasdaq may grant a second 180‑day grace period, provided the company meets other initial Nasdaq Capital Market listing standards and informs Nasdaq of its intent to cure the bid‑price deficiency.
What are the delisting risks for Traws Pharma (TRAW) after this Nasdaq notice?
If Traws Pharma does not regain or maintain compliance within the allowed periods, Nasdaq may delist its common stock. The company would receive delisting notice and could appeal to a Nasdaq hearings panel, but there is no assurance an appeal would succeed.
Does the Nasdaq bid-price notice immediately affect trading in Traws Pharma (TRAW) stock?
The notice has no immediate effect on Traws Pharma’s Nasdaq Capital Market listing. Its common stock continues to trade as before while the company works within the 180‑day compliance period to address the minimum bid price deficiency.